Cargando…
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic pathways involved in IPF have not been fully elucidated, IPF is believed to be caused by repetitive alveolar epithelia...
Autores principales: | Wollin, Lutz, Wex, Eva, Pautsch, Alexander, Schnapp, Gisela, Hostettler, Katrin E., Stowasser, Susanne, Kolb, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416110/ https://www.ncbi.nlm.nih.gov/pubmed/25745043 http://dx.doi.org/10.1183/09031936.00174914 |
Ejemplares similares
-
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015) -
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019) -
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020) -
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017) -
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)